Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2014-05-08

FDA Approved: TRILEPTAL — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplemental application for Trileptal (oxcarbazepine) submitted by Novartis Pharmaceuticals Corporation, resulting in changes to its labelin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TRILEPTAL (OXCARBAZEPINE)

Snippet

SUPPL AP for TRILEPTAL (OXCARBAZEPINE)